ALN-VSP: Phase I started

Alnylam began an open-label, U.S. Phase I trial to evaluate intravenous ALN-VSP in about 55 patients. The company developed ALN-VSP using Tekmira's stable nucleic acid-lipid particles (SNALP) technolo...